Quick Takeaways
- This page summarizes Fred E. Cohen's Form 4 filing for UroGen Pharma Ltd. (URGN).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 10 Jun 2022, 15:37.
Fred E. Cohen - 08 Jun 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)
- Role
- Director
- Signature
- /s/ Jason Smith, Attorney-in-Fact
- Issuer symbol
- URGN
- Transactions as of
- 08 Jun 2022
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 10 Jun 2022, 15:37:08 UTC
- Previous filing
- 26 Oct 2021
- Next filing
- 16 Jun 2022
- SEC
- View on sec.gov
Quoteable Key Fact
"Fred E. Cohen filed Form 4 for UroGen Pharma Ltd. (URGN) on 10 Jun 2022."
What Changed
- Previous filing in this sequence was filed on 26 Oct 2021.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | URGN | Stock Option (right to buy) | Award | $0 | +10,000 | $0.000000 | 10,000 | 08 Jun 2022 | Ordinary Shares | 10,000 | $7.06 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The shares underlying the stock option will vest in equal quarterly installments over a period of one year. |